BobbyPeruJLTC Posted - 6 days ago

$AVDL down like 36 k today. Seen this before. Bear raid or manipulation or whatever. Don’t care. Sell your cheap shares. I see this rebounding

BobbyPeruJLTC Posted - 6 days ago

$AVDL damn I’m down 36k on this today. Not selling. Seen it over and over with stock. Pure manipulation

Maximus12 Posted - 6 days ago

$AVDL Think decision will be by Memorial Day

patc1 Posted - 1 week ago

$AVDL Oppenhiemer today On Friday afternoon, we listened to the scheduled APA suit of JAZZ vs. FDA related to the approval and Orphan Drug Exclusivity (ODE) of AVDL's Lumryz and come away with reaffirmed confidence in a favorable outcome for AVDL and patients. While litigations can get quite complex and outcomes can be difficult to predict, we didn't hear anything new, surprising, or concerning during the hearing. In terms of next steps, we believe a decision can take another 2-4 months. Coming off a strong 1Q24 and confidence in continued momentum, we are reiterating our Outperform rating and $29 price target.

NewbieMe21 Posted - 1 week ago

$AVDL What’s the time frame for the Judge’s ruling?

Everest17 Posted - 1 week ago

$AVDL Weird. Jazz chief Legal Officer sold off $580k of her shares. 12% of her position. Just days before their trial……..

Everest17 Posted - 1 week ago

$AVDL We crushing Jazz in court?

ElectricJ Posted - 1 week ago

$AVDL comeback time

Thestocktraderhubzee Posted - 1 week ago

$AVDL HC Wainwright & Co. Maintains Buy on Avadel Pharmaceuticals, Raises Price Target to $27

Magic8BallResponse Posted - 1 week ago

$AVDL Orexin agonists are coming to a theater near you !!!!!

DonCorleone77 Posted - 1 week ago

$AVDL Avadel Pharmaceuticals price target raised to $23 from $22 at Craig-Hallum Craig-Hallum raised the firm's price target on Avadel Pharmaceuticals to $23 from $22 and keeps a Buy rating on the shares. The firm says the quarter results indicate a continuation of strong fundamentals for Lumryz in Q1. Craig-Hallum thinks the stock's negative reaction really centers around one thing. Patients on drug grew 70% quarter-over-quarter versus 40% revenue growth. There was general concern on the call that this disconnect may be related to a material step up in discontinuations. While discontinuations always play a role, the firm notes that as deductibles reset in Q1 for patients, this leads to industry-wide higher gross-to-net payouts, putting a headwind on net revenue per patient as companies must pay more in copay assistance.

Mrmondial Posted - 1 week ago

$AVDL what offering ? Seems like it’s just a replacement to a previous agreement in place and they had to change the agreement to reflect the shares as ordinary shares instead of the ADRs No ??

Otus Posted - 1 week ago

$AVDL I feel betrayed. Very very unhappy with the offering.

LarryYMB Posted - 1 week ago

$AVDL Listening the call, nothing surprising, IH starting soon, the FDA going to b1tch slap cousin bruce and after there is no risk left!

BobbyPeruJLTC Posted - 1 week ago

$AVDL profitable this year. A candidate for a bigger fish to swallow this company up.

Otus Posted - 1 week ago

$AVDL I’d guess we close mid to high 17’s. I’m good with that. If it happens!

Otus Posted - 1 week ago

$AVDL so far not excited by this call.

epsguid Posted - 1 week ago

$AVDL reported a loss of $0.30, consensus was $0.03, Earnings Whisper was $0.06 via @eWhispers #whispermiss http://eps.sh/d/avdl

DonCorleone77 Posted - 1 week ago

$AVDL Avadel Pharmaceuticals reports Q1 EPS (30c), consensus (21c) Reports Q1 revenue $27.178M, consensus $25.9M. "We are pleased to report another strong quarter of launch performance from LUMRYZ as we continue to serve the narcolepsy patient community. The continued positive feedback we hear daily from patients, prescribers and caregivers builds on the strong commercial foundation we established early into the launch," said Greg Divis, Chief Executive Officer of Avadel Pharmaceuticals. "Over the course of 2024, we will be laser focused on the continued market growth of LUMRYZ for the treatment of narcolepsy as well as potentially expanding to the pediatric population and initiating our Phase 3 pivotal trial in idiopathic hypersomnia in the second half of the year."

Stock_Titan Posted - 1 week ago

$AVDL Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial Results https://www.stocktitan.net/news/AVDL/avadel-pharmaceuticals-provides-corporate-update-and-reports-first-xvjqcqnxqqdk.html

DonCorleone77 Posted - 1 week ago

@MaverikIT @net0trader @Wigglyick @Cash4freedom @RonIsWrong @Im_not_Mr_Lebowski @IsabellaDC @CycleTrade @bearcharts $AVDL - These guys announce tomorrow PM. Might want to keep at least one eye on them. Up 6% after breaking out from a late stage 1 base about a month ago. Moving averages all lined up in proper sequence. Pretty much tested 21EMA today and found support. According to someone much, much, much smarter than me, they might be poised to keep taking narcolepsy market share from $JAZZ. As always, earnings reports and guidance are binary events so exercise the appropriate caution:

Otus Posted - 1 week ago

$AVDL looks like positioning for tomorrow. Let’s hope they exceed expectations.

Otus Posted - 2 weeks ago

$AVDL I’m happy to say it’s all about earnings at this point. What a different company we own now as opposed to a year ago! Hopefully management delivers what most of us expect. I’m confident. Couple major changes though. Now that we are revenue company we ride based on that. Additionally, volatility should be significantly lower that what we have had in prior years with less manipulation. The bad, and this is my opinion only, the days of the shorter term multi bagger is no longer there. Doubling possible but this is a different company now. I have trimmed my holding in the last month but I still have a fairly significant retail position. Good fortune to all long holders!!

ElectricJ Posted - 2 weeks ago

$AVDL

LarryYMB Posted - 2 weeks ago

$AVDL HAHHA go baby go !

speed717 Posted - 2 weeks ago

$AVDL A warning to anyone holding a short position in AVDL, the share will be added to various Russell indexes at the end of the quarter. Index trackers will need to buy upwards of 15million shares. With 10.6 million short, that’s a lot of competition for shares. EPS on 5/8 should ignite the fuse. Gonna be fun to watch.

Stock_Titan Posted - 2 weeks ago

$AVDL Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8 https://www.stocktitan.net/news/AVDL/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-wd4lunrqfzsk.html

ElectricJ Posted - 04/30/24

$AVDL strong on bad day for markets...

Everest17 Posted - 04/29/24

$AVDL No volume Everyone wants a Tesla

FactsPlease99 Posted - 04/26/24

$AVDL Avadel is a joke of an investment. LUMRYZ is not doing as well as it was expected to do, FACT. There is zero pipeline FACT. Zero research FACT. Garbage risky investment